HomeAI · summaries
Storia in 4 fonti
Why Is Capricor Therapeutics Stock Trading Higher on Monday? - Capricor Therapeutics (NASDAQ:CAPR)
Capricor stock rises as FDA extends its deramiocel review to Nov. 22 following new Phase 3 HOPE-3 data and an advisory panel setback.
Confronto fonti
4 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
FDA extends review of Capricor cell therapy; Pain drug startup to go public
The agency is now reviewing an updated application for deramiocel with a “refined” indication. Elsewhere, a startup co-founded by Vivek Ramaswamy is taking a speedy path to the…
- ·
endpoints.news
Capricor's Duchenne cell therapy gets PDUFA date extended as FDA reviews new data
FDA delays Capricor's deramiocel decision to Nov. 22, reviewing new HOPE-3 data for narrower upper limb indication in Duchenne muscular dystrophy patients.
